Review

Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications†

  1. Zhenyu Yue PhD1,*,
  2. M. Lenard Lachenmayer MD1,2

Article first published online: 29 APR 2011

DOI: 10.1002/mds.23737

Issue

Movement Disorders

Movement Disorders

Volume 26, Issue 8, pages 1386–1397, July 2011

Additional Information

How to Cite

Yue, Z. and Lachenmayer, M. L. (2011), Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov. Disord., 26: 1386–1397. doi: 10.1002/mds.23737

Author Information

  1. 1

    Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA

  2. 2

    Department of Neurology, University of Bonn, Bonn, Germany

*Department of Neurology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA

  1. †

    Funding agencies: This work was supported by NIH/NINDS grants NS060809-01 and NS072359-01 and the Michael J. Fox Foundation for Parkinson's Research.Relevant conflicts of interest/financial disclosures: Nothing to report.Full financial disclosures and author roles may be found in the online version of this article.

Publication History

  1. Issue published online: 21 JUL 2011
  2. Article first published online: 29 APR 2011
  3. Manuscript Accepted: 10 MAR 2011
  4. Manuscript Revised: 1 MAR 2011
  5. Manuscript Received: 2 FEB 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (225K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Erwan Bezard, Zhenyu Yue, Deniz Kirik, Maria Grazia Spillantini, Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies, Movement Disorders, 2013, 28, 1
    Direct Link:
  2. 2
    Zhenyu Yue, X William Yang, Dangerous duet: LRRK2 and α-synuclein jam at CMA, Nature Neuroscience, 2013, 16, 4, 375

    CrossRef

  3. 3
    Juliet M. Taylor, Bevan S. Main, Peter J. Crack, Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease, Neurochemistry International, 2013, 62, 5, 803

    CrossRef

  4. 4
    David T. Dexter, Peter Jenner, Parkinson disease: from pathology to molecular disease mechanisms, Free Radical Biology and Medicine, 2013,

    CrossRef

  5. 5
    Jingwen Niu, Mei Yu, Chunyan Wang, Zhiheng Xu, Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein, Journal of Neurochemistry, 2012, 122, 3
    Direct Link:
  6. 6
    Kelly M Hinkle, Mei Yue, Bahareh Behrouz, Justus C Dächsel, Sarah J Lincoln, Erin E Bowles, Joel E Beevers, Brittany Dugger, Beate Winner, Iryna Prots, Caroline B Kent, Kenya Nishioka, Wen-Lang Lin, Dennis W Dickson, Christopher J Janus, Matthew J Farrer, Heather L Melrose, LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors, Molecular Neurodegeneration, 2012, 7, 1, 25

    CrossRef

  7. 7
    Z. Sheng, S. Zhang, D. Bustos, T. Kleinheinz, C. E. Le Pichon, S. L. Dominguez, H. O. Solanoy, J. Drummond, X. Zhang, X. Ding, F. Cai, Q. Song, X. Li, Z. Yue, M. P. van der Brug, D. J. Burdick, J. Gunzner-Toste, H. Chen, X. Liu, A. A. Estrada, Z. K. Sweeney, K. Scearce-Levie, J. G. Moffat, D. S. Kirkpatrick, H. Zhu, Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations, Science Translational Medicine, 2012, 4, 164, 164ra161

    CrossRef

  8. 8
    Thomas Kramer, Fabio Lo Monte, Stefan Göring, Ghislaine Marlyse Okala Amombo, Boris Schmidt, Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models, ACS Chemical Neuroscience, 2012, 3, 3, 151

    CrossRef

  9. 9
    Guoxiang Liu, Leonardo Aliaga, Huaibin Cai, α-synuclein, LRRK2 and their interplay in Parkinson’s disease, Future Neurology, 2012, 7, 2, 145

    CrossRef

View Full Article (HTML) Get PDF (225K)